Kura Oncology Inc. (KURA) Reaches New 52-Week Low at $2.50
Shares of Kura Oncology Inc. (NASDAQ:KURA) hit a new 52-week low during trading on Tuesday . The stock traded as low as $2.50 and last traded at $2.50, with a volume of 90,077 shares trading hands. The stock had previously closed at $2.68.
A number of equities analysts have commented on the company. Citigroup Inc. reduced their price objective on Kura Oncology from $19.00 to $12.00 and set a “buy” rating on the stock in a research note on Monday, March 21st. Zacks Investment Research raised Kura Oncology from a “hold” rating to a “buy” rating and set a $4.75 price objective on the stock in a research note on Tuesday, March 22nd. Finally, Oppenheimer Holdings Inc. reissued an “outperform” rating and issued a $16.00 price objective on shares of Kura Oncology in a research note on Tuesday, June 21st.
The firm’s market cap is $47.94 million. The company has a 50-day moving average price of $2.91 and a 200-day moving average price of $4.08.
Kura Oncology (NASDAQ:KURA) last announced its earnings results on Wednesday, May 11th. The company reported ($0.36) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.35) by $0.01. On average, equities research analysts expect that Kura Oncology Inc. will post ($1.70) EPS for the current year.
Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.